Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals

Mattia Crespi, Maria Giulia Demarzo, Matteo Brunacci, Gaia Pellegatta, Fabio Ferrando, Alberto Ballestrero, Federica Grillo, Vincenzo Savarino, Edoardo G. Giannini

Research output: Contribution to journalArticlepeer-review


Chronic hepatitis C (HCV) virus infection may be associated with several non-hepatic manifestations, mainly driven by chronic immune stimulation, such as mixed cryoglobulinemia and Non-Hodgkin's Lymphoma. This association has been proved by several meta-analyses and some interventional studies demonstrating that antiviral treatment may be effective in inducing HCV-associated lymphoma regression. The recent advent of direct acting antivirals (DAAs) in the therapeutic armamentarium of HCV infection made possible treatment of patients with advanced liver disease. Here we report on a rare association of a cirrhotic patient with HCV and Waldenström's Macroglobulinemia with severe cryoglobulinemia, who had already failed an interferon-based antiviral regimen, whose haematologic disease was ameliorated by HCV eradication following treatment with sofosbuvir and simeprevir with ribavirin, and where successful treatment was accompanied also by consistent improvement in liver function and parameters of portal hypertension.

Original languageEnglish
Pages (from-to)1072-1077
Number of pages6
JournalAnnals of Hepatology
Issue number6
Publication statusPublished - Oct 16 2018


  • Cirrhosis
  • Haematology
  • Outcome
  • Portal hypertension

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals'. Together they form a unique fingerprint.

Cite this